JDDW 2017 Close

Keyword Search
>Adding space between the words will produce results as inserting the word "AND".
International Session (Symposium)5 (JSGE・JGES・JSH・JSGS)
Fri. October 13th   9:00 - 12:00   Room 11: Fukuoka International Congress Center 502+503
Recent updates on the role of chemotherapy in pancreatic cancer
H. Ueno
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital
Pancreatic cancer is a fatal disease, with a 5-year survival rate of less than 5%. Surgery remains the only curative option, but most patients have metastatic pancreatic cancer (MPC) at the time of diagnosis. Systemic chemotherapy with single-agent gemcitabine has been regarded as a standard treatment for MPC for many years. However, recently, in randomized phase III trials, two regimens, gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX, have shown a clear survival benefit over gemcitabine alone. With the emergence of GnP and FOLFIRINOX, an increasing number of patients with MPC have been given a chance to receive treatment with better survival benefit, but long-term effects of these treatments have yet been unsatisfactory. To develop a more effective treatment regimen, many studies evaluating newer drugs, including molecular targeted agents or immunotherapies, are ongoing worldwide. On the other hand, in the absence of clinical trials that directly compare the effectiveness of GnP and FOLFIRINOX, it is difficult to determine which regimen should be employed for patients with MPC in clinical practice. A recent phase I study conducted by our group suggests that S-1 + irinotecan + oxaliplatin (S-IROX) may be effective in treating MPC, and a large phase III study that compares GnP vs. FOLFIRINOX vs. S-IROX is now underway in Japan. In this session, the current status of systemic chemotherapy for MPC will be discussed.
Index Term 1: pancreatic cancer
Index Term 2: chemotherapy
Page Top